Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Drug Delivery
EyePoint reports Duravyu trial fail, raising questions
Targeting a major market in retinal diseases, EyePoint has revealed that its lead candidate failed to meet its primary endpoint in a phase 2 trial.
Eric Sagonowsky
May 6, 2024 10:55am
Amylyx to pull failed ALS drug from market, cut 70% of staff
Apr 4, 2024 10:06am
EU regulators recommend pulling Novartis sickle cell med Adakveo
May 26, 2023 11:18am
FibroGen's AZ deal in danger after anemia drug fails in 2nd act
May 5, 2023 9:53am
Phase 2 flop causes Endo's frozen shoulder plan to come unstuck
Jul 5, 2022 8:45am
NuCana's twist on chemo drug Gemzar fails in phase 3 again
Mar 8, 2022 7:35am